same as IMP (Tildacerfont) minus the active substance clinical trials

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

This study is looking into a new medication called Tildacerfont for adults with a condition called classic congenital adrenal hyperplasia. It aims to see if Tildacerfont can help reduce the amount of steroid medicine (like hydrocortisone or prednisolone) people need to take.